Table 1. Clinical and Demographic Features of the Escalation and Early Intensive Treatment Cohorts.
| Variable | Treatment Group | P Value | |
|---|---|---|---|
| Early Intensive (n = 104) | Escalation (n = 488) | ||
| Women, No. (%) | 79 (76) | 346 (71) | .37 |
| Age at symptom onset, mean (SD), y | 29.8 (9.2) | 30.2 (9.4) | .73 |
| Age at first DMT, mean (SD), y | 34.0 (9.0) | 38.5 (9.7) | <.001 |
| EDSS score at DMT onset, median (IQR) | 3.5 (2.0-5.0) | 3.5 (2.0-5.0) | .55 |
| Follow-up duration, mean (SD), y | 5.8 (3.6) | 6.9 (5.3) | .30 |
| Baseline (pretreatment) ARR, median (IQR) | 1.7 (0.9-2.8) | 0.7 (0.4-1.3) | <.001 |
| Posttreatment ARR, median (IQR) | 0 (0-0.3) | 0.16 (0-0.5) | .02 |
| Median calendar year of first DMT | 2010 | 2011 | .84 |
Abbreviations: ARR, annualized relapse rate; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; IQR, interquartile range.